Trial · NCT07911514
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum observed plasma concentration (Cmax) | Plasma sample collection from pre dose to Day 22 | Assess the relative bioavailability (rBA) and compare single subcutaneous (SC) dose pharmacokinetics (PK) of concomitant doses of AZD9550 and AZD6234 to different fixed-dose coformulations |
| Primary | Area under the curve from time 0 to the time of last quantifiable concentration (AUClast) | Plasma sample collection from pre dose to Day 22 | Assess the relative bioavailability (rBA) and compare the single subcutaneous (SC) dose pharmacokinetics (PK) of concomitant doses of AZD9550 and AZD6234 to different fixed-dose coformulations |
| Primary | Area under the curve from time 0 extrapolated to infinity (AUCinf) | Plasma sample collection from pre dose to Day 22 | Assess the relative bioavailability (rBA) and compare the single subcutaneous (SC) dose pharmacokinetics (PK) of concomitant doses of AZD9550 and AZD6234 to different fixed-dose coformulations |
| Secondary | Number of participants with adverse events (AEs)/serious AEs (SAEs), and change from baseline for vital signs, electrocardiograms (ECGs), and laboratory safety tests | Through study duration, approximately 9 weeks | Safety and tolerability of single concomitant doses and different fixed-dose coformulations of AZD9550 and AZD6234 following a single subcutaneous (SC) dose |
| Secondary | Time of maximum observed concentration (tmax) | Plasma sample collection from pre dose to Day 22 | Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations |
| Secondary | Time of last measurable observed concentration (tlast) | Plasma sample collection from pre dose to Day 22 | Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformuations |
| Secondary | Time prior to the first measurable concentration (tlag) | Plasma sample collection from pre dose to Day 22 | Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations |
| Secondary | Terminal elimination half-life (t1/2λz) | Plasma sample collection from pre dose to Day 22 | Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations |
| Secondary | Apparent total body clearance (CL/F) | Plasma sample collection from pre dose to Day 22 | Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations |
| Secondary | Apparent volume of distribution based on the terminal phase (Vz/F) | Plasma sample collection from pre dose to Day 22 | Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations |
| Secondary | Mean residence time from time 0 extrapolated to infinity (MRTinf) | Plasma sample collection from pre dose to Day 22 | Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations |
| Secondary | First order rate constant associated with the terminal (log-linear) portion of the curve (λz) | Plasma sample collection from pre dose to Day 22 | Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07911514/registered